NTII Neurobiological Technologies (MM)

Neurobiological Technologies Names David E. Levy, M.D., As Vice President of Clinical Development to Lead Viprinex(TM) Team RICHMOND, Calif., Aug. 23 /PRNewswire-FirstCall/ -- Neurobiological Technologies, Inc. (NTI(R)) (NASDAQ:NTII) today announced that on September 1, 2004, David E. Levy, M.D., will join the company as vice president of clinical development, a newly created position. Initially, Dr. Levy will lead the clinical development effort for Viprinex(TM) (ancrod), a late-stage reperfusion therapy for use in the treatment of acute ischemic stroke. NTI obtained rights to Viprinex through its acquisition of Empire Pharmaceuticals in July 2004. "Viprinex was initially developed by Knoll Pharmaceuticals, where Dr. Levy was in charge of the clinical program. He has extensive experience in the area of stroke therapy and comes to NTI with expertise successfully directing major clinical programs in CNS," said Paul E. Freiman, Neurobiological Technologies' president and chief executive officer. "We believe David is ideally suited to help lead NTI's stroke program and our planned Viprinex Phase III clinical trials, as well as other clinical efforts at the company. We expect that he will be a tremendous asset to NTI and we are delighted that he will be joining our team." Levy joins NTI after 14 years in the pharmaceutical industry preceded by an illustrious academic career. Most recently, he was international project team leader at Eisai Medical Research, Inc. where he directed a clinical program to develop a novel, new therapy in Alzheimer's disease as well as acute ischemic stroke programs. Previously, he served as an advisor to Empire Pharmaceuticals and as senior director of medical research at DOV Pharmaceutical, where he directed several clinical development programs. From 1991 to 2001, Dr. Levy was with Knoll Pharmaceuticals, serving initially as senior director and therapeutic head of clinical CNS and then as senior director of cardiovascular/internal medicine. At Knoll, he directed the group that designed and conducted one of the world's only successful therapeutic studies of acute ischemic stroke. Dr. Levy's academic career includes 23 years at Weill-Cornell Medical College and New York Presbyterian Hospital, where he was an intern and resident from 1968 through 1970 and served as executive vice chair of neurology from 1988 to 1991. He continues to serve as adjunct associate professor of neurology and adjunct associate attending neurologist at these institutions. He is certified by the American Board of Psychiatry and Neurology, the American Board of Internal Medicine, and is licensed to practice medicine in New York State. Among his professional affiliations, Levy is a fellow of the American Academy of Neurology, the American College of Physicians, and the Stroke Counsel of the American Heart Association. He is widely published in the areas of cerebrovascular disease, including ischemic stroke and central nervous system disorders. Levy earned his bachelor of arts degree in chemistry and physics, cum laude, from Harvard College and his doctor of medicine degree from Harvard Medical School. About Neurobiological Technologies, Inc. (NTI) NTI is an emerging drug development company focused on the clinical evaluation and regulatory approval of neuroscience drugs. The company's strategy is to in-license and develop early- and later-stage drug candidates that target major medical needs and that can be rapidly commercialized. Its management team oversees the human clinical trials necessary to establish preliminary evidence of efficacy and seeks partnerships with pharmaceutical and biotechnology companies to complete development and marketing of its product candidates. Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including, but not limited to, our ability to develop and meet regulatory requirements for our products, including Viprinex, the inherent risk of failure in developing product candidates based on new technologies, the risks of acquiring companies and new technologies and other risks detailed from time to time in the Company's Securities and Exchange Commission filings. Actual results may differ materially from those projected. These forward-looking statements represent management's judgment as of the date of this release. The company disclaims, however, any intent or obligation to update these forward-looking statements. DATASOURCE: Neurobiological Technologies, Inc. CONTACT: Paul E. Freiman, President & CEO of Neurobiological Technologies, Inc., +1-510-262-1730; or Roger Pondel or Rob Whetstone, both of PondelWilkinson Inc., +1-310-279-5980, for Neurobiological Technologies, Inc. Web site: http://www.ntii.com/

Copyright